{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T23:46:54Z","timestamp":1750981614393},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1709","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>The adeno-associated virus (AAV) vector-based gene therapy delandistrogene moxeparvovec-rokl (Elevidys \u2013 Sarepta) received accelerated approval from the FDA in 2023 for treatment of ambulatory children 4-5 years old with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in the DMD gene.1 It has now received full approval for use in ambulatory patients \u22654 years old and accelerated approval for use in nonambulatory patients with DMD.<\/jats:p>","DOI":"10.58347\/tml.2024.1709e","type":"journal-article","created":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T17:03:43Z","timestamp":1723741423000},"page":"135-136","source":"Crossref","is-referenced-by-count":2,"title":["In Brief: Expanded Indication for Elevidys"],"prefix":"10.58347","volume":"66","author":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"37151","published-online":{"date-parts":[[2024,8,19]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T17:03:47Z","timestamp":1723741427000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1709e"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,19]]},"references-count":0,"journal-issue":{"issue":"1709","published-online":{"date-parts":[[2024,8,19]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2024.1709e","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,19]]}}}